Live search
TopFind is fetching the latest matches for your search.
We reviewed 4 live results for fasenra and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biologics and Respiratory Health.
Source: AstraZeneca Pharmaceuticals (Phils.), Inc.
Description
Fasenra is a prescription biologic medication used as an add-on maintenance treatment for adults and children aged 6 years and older with severe eosinophilic asthma. As a monoclonal antibody, it targets and removes eosinophils, a type of white blood cell that causes lung inflammation. It is administered via subcutaneous injection, typically every 4 weeks for the first three doses and every 8 weeks thereafter, using a single-dose pre-filled syringe or the Fasenra Pen autoinjector.
Best for
severe eosinophilic asthma patients, biologic maintenance therapy, long-term asthma control and pediatric and adult patients
Rating
Source: Specialty Healthcare Providers (Philippines)
Description
Specialized sourcing and administration services for Fasenra (benralizumab) within high-tier medical facilities. These providers ensure the necessary cold-chain logistics (2°C to 8°C) required to maintain the efficacy of biologic medications and provide professional clinical administration for subcutaneous injections.
Best for
cold-chain medication management, hospital-based administration, verified biologic sourcing and patients at major medical centers
Rating
Source: AstraZeneca Malaysia
Description
Fasenra (Benralizumab) is an immunomodulatory biologic available in a 30mg pre-filled pen, typically used for severe eosinophilic asthma.
Best for
severe asthma, eosinophilic conditions and monoclonal antibody therapy
Rating
| Compare | Fasenra (benralizumab) | Fasenra Specialty Pharmacy Sourcing | Fasenra |
|---|---|---|---|
| Source | AstraZeneca Pharmaceuticals (Phils.), Inc. | Specialty Healthcare Providers (Philippines) | AstraZeneca Malaysia |
| Description | Fasenra is a prescription biologic medication used as an add-on maintenance treatment for adults and children aged 6 years and older with severe eosinophilic asthma. As a monoclonal antibody, it targets and removes eosinophils, a type of white blood cell that causes lung inflammation. It is administered via subcutaneous injection, typically every 4 weeks for the first three doses and every 8 weeks thereafter, using a single-dose pre-filled syringe or the Fasenra Pen autoinjector. | Specialized sourcing and administration services for Fasenra (benralizumab) within high-tier medical facilities. These providers ensure the necessary cold-chain logistics (2°C to 8°C) required to maintain the efficacy of biologic medications and provide professional clinical administration for subcutaneous injections. | Fasenra (Benralizumab) is an immunomodulatory biologic available in a 30mg pre-filled pen, typically used for severe eosinophilic asthma. |
| Best for | severe eosinophilic asthma patients, biologic maintenance therapy, long-term asthma control and pediatric and adult patients | cold-chain medication management, hospital-based administration, verified biologic sourcing and patients at major medical centers | severe asthma, eosinophilic conditions and monoclonal antibody therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Fasenra (benralizumab) from AstraZeneca Pharmaceuticals (Phils.), Inc.."
I picked this because AstraZeneca is the manufacturer and official registrant of Fasenra, providing the most direct and reliable access to this advanced asthma biologic in the Philippines.